Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Baylor College of Medicine
Ossium Health, Inc.
Ohio State University Comprehensive Cancer Center
Children's Hospital of Philadelphia
University College, London
National Cancer Institute (NCI)
Baylor College of Medicine
St. Jude Children's Research Hospital
Wugen, Inc.
Ohio State University Comprehensive Cancer Center
Baylor College of Medicine
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Medical College of Wisconsin
City of Hope Medical Center
Washington University School of Medicine
Tr1X, Inc.
Chongqing Precision Biotech Co., Ltd
New York Medical College
Boehringer Ingelheim
Beijing Boren Hospital
Beijing Boren Hospital
Therapeutic Advances in Childhood Leukemia Consortium
Stanford University
University of Miami
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Stanford University
Hebei Senlang Biotechnology Inc., Ltd.
Shenzhen Geno-Immune Medical Institute
University of Nebraska
M.D. Anderson Cancer Center
Emory University
Shanghai Pudong Hospital
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Shenzhen Geno-Immune Medical Institute
National University Hospital, Singapore
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
miRagen Therapeutics, Inc.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Jonsson Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
University of Wisconsin, Madison
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Bristol-Myers Squibb
Swiss Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center